More on EXEL

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-50.0% Growth)
- Ratings (5.6 Score)
- Holders
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/11/16 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Exelixis (NQ:EXEL)
Delayed: 7.80 +0.02 (0.26%)
Trade Now!
Prev. Close $7.78  
Open$7.90 
52 Wk High$7.88 
52 Wk Low$3.31 
Day High$7.90 
Day Low$7.63 
P/E N/A  
EPS$-1.33 
Volume6,261,065 

Friends, Peers and Foes (?): IPN, IPSEY, RHHBY, EXEK, KITE (more...)

Jun 22, 2016 03:33 PM Notable 52-Week Highs and Lows 6/22: (NFX) (EXEL) (CSAL) High; (ALXN) (BIIB) Low
Jun 21, 2016 07:16 AM Exelixis (EXEL) PT Raised to $10 at Leerink on CRC Opportunity for Cotellic
Jun 6, 2016 03:26 PM Notable 52-Week Highs and Lows 6/6: (EXEL) (BMY) (WCN) High; (MRTX) (DNAI) (AZUR) Low
Jun 6, 2016 07:36 AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 6, 2016 07:30 AM Exelixis (EXEL), Ipsen Announce Positive METEOR Trial Subgroup Analyses in RCC
Jun 6, 2016 07:30 AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 6, 2016 06:37 AM Exelxis (EXEL) Cobi Phase Ib Data and Phase III Launch in CRC a Positive - Leerink
Jun 5, 2016 07:53 AM Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Re
Jun 5, 2016 07:36 AM Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced re
Jun 5, 2016 07:30 AM Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
View All Articles